Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Hypoglycaemia is the limiting factor in the glycaemic management of diabetes. Iatrogenic hypoglycaemia is typically the result of the interplay of insulin excess and compromised glucose counterregulation in Type I (insulin-dependent) diabetes mellitus. Insulin concentrations do not decrease and glucagon and epinephrine concentrations do not increase normally as glucose concentrations decrease. The concept of hypoglycaemia-associated autonomic failure (HAAF) in Type I diabetes posits that recent antecedent iatrogenic hypoglycaemia causes both defective glucose counterregulation (by reducing the epinephrine response in the setting of an absent glucagon response) and hypoglycaemia unawareness (by reducing the autonomic and the resulting neurogenic symptom responses). Perhaps the most compelling support for HAAF is the finding that as little as 2 to 3 weeks of scrupulous avoidance of hypoglycaemia reverses hypoglycaemia unawareness and improves the reduced epinephrine component of defective glucose counterregulation in most affected patients. The mediator and mechanism of HAAF are not known but are under active investigation. The glucagon response to hypoglycaemia is also reduced in patients approaching the insulin deficient end of the spectrum of Type II (non-insulin-dependent) diabetes mellitus, and glycaemic thresholds for autonomic (including epinephrine) and symptomatic responses to hypoglycaemia are shifted to lower plasma glucose concentrations after hypoglycaemia in Type II diabetes. Thus, patients with advanced Type II diabetes are also at risk for HAAF. While it is possible to minimise the risk of hypoglycaemia by reducing risks -- including a 2 to 3 week period of scrupulous avoidance of hypoglycaemia in patients with hypoglycaemia unawareness -- methods that provide glucose-regulated insulin replacement or secretion are needed to eliminate hypoglycaemia and maintain euglycaemia over a lifetime of diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because of steady improvements in the glycemic management of diabetes, it is possible both to improve glycemic control and to minimize the risk of hypoglycemia in many patients (12, 16, 84 -86).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoglycemia in diabetes is fundamentally the result of treatments that raise insulin levels and thus lower plasma glucose concentrations (12,16,84,85).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Those treatments include insulin or insulin secretagogues such as a sulfonylurea or a nonsulfonylurea insulin secretagogue (e.g.nateglinide or repaglinide).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In type 1 diabetes, deficiency of the secretory response of glucagon to hypoglycemia is an early acquired abnormality of counterregulation.The catecholamine response compensates for several years but declines with time (1).”
From Hypoglycemia in Type 2 Diabetes (2005) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Treatment-induced hypoglycemia is the limiting factor in the glycemic management of diabetes (12,16,84).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Plum, F. (1960) · Archives of Neurology · doi:10.1001/archneur.1960.03840090124020 · Cited by 10,364
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 2×
“Enough insulin, or any effective drug, to lower plasma glucose concentrations to or below the normal range would eliminate the symptoms of hyperglycaemia, prevent the acute hyperglycaemic complications (ketoacidosis, hyperosmolar syndrome), almost assuredly prevent the long-term microvascular complications [1, 2] and…”
BackgroundKhaw, K.-T. (2001) · BMJ · doi:10.1136/bmj.322.7277.15 · Cited by 1,017
Gold, A. E., Macleod, K. M., & Frier, B. M. (1994) · Diabetes Care · doi:10.2337/diacare.17.7.697 · Cited by 810
Gerich, J. E., Langlois, M., Noacco, C., Karam, J. H., & Forsham, P. H. (1973) · Science · doi:10.1126/science.182.4108.171 · Cited by 688 · cited 1×
“Finally, we and others have begun to study the mechanisms of the normal glucagon response to hypoglycaemia with the aim of gaining insight into the mechanism of the absence of the glucagon response in Type I diabetes [22], a critical component of defective glucose counterregulation and HAAF.”
BackgroundMitrakou, A., Ryan, C., Veneman, T., Mokan, M., Jenssen, T., Kiss, I., Durrant, J., Cryer, P., & Gerich, J. (1991) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1991.260.1.e67 · Cited by 558 · cited 2×
“0 mmol/l (54 mg/dl) respectively) are reproducible in healthy subjects [13, 14, 15], they shift to higher plasma glucose concentrations in poorly controlled diabetes [16, 17] and to lower plasma glucose concentrations following episodes of hypoglycaemia [18, 19, 20, 21].”
BackgroundSelf-citationHeller, S. R., & Cryer, P. E. (1991) · Diabetes · doi:10.2337/diab.40.2.223 · Cited by 531
Self-citation&NA; (1994) · Survey of Anesthesiology · doi:10.1097/00132586-199406000-00052 · Cited by 487
Dagogo-Jack, S. E., Craft, S., & Cryer, P. E. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116302 · Cited by 471
Self-citation
Cited by
Items 301–400 of 793
Liu, W., Yang, X., & Huang, J. (2018) · International Journal of Endocrinology · doi:10.1155/2018/8726046 · Cited by 32
“The burden and fear of hypoglycemia have become major barriers to patients reaching the recommended HbA1c level [5].”
BackgroundBähr, I., Mühlbauer, E., Albrecht, E., & Peschke, E. (2012) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2012.01009.x · Cited by 36
“Therefore, the risk of episodes of severe hypoglycemia is increased in both type 1 and type 2 diabetes [3].”
BackgroundOne-step purification of functional human and rat pancreatic alpha cells
Köhler, M. G., Daré, E., Ali, M. Y., Rajasekaran, S. S., Moede, T., Leibiger, B., Leibiger, I. B., Tibell, A., Juntti‐Berggren, L., & Berggren, P. (2012) · Integrative Biology · doi:10.1039/c2ib00125j · Cited by 31
Haidar, A., Legault, L., Raffray, M., Gouchie‐Provencher, N., Jacobs, P. G., Fathi, A. E., Rutkowski, J., Messier, V., & RABASA-LHORET, R. P. R. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0365 · Cited by 34
Harris, S. B., Khunti, K., Landin‐Olsson, M., Galbo-Jørgensen, Bøgelund, Chubb, Gundgaard, & Evans, M. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s46805 · Cited by 31
Increased Brain Transport and Metabolism of Acetate in Hypoglycemia Unawareness
Gulanski, B., Feyter, H. M. D., Page, K. A., Belfort‐DeAguiar, R., Mason, G. F., Rothman, D. L., & Sherwin, R. S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1701 · Cited by 33
Huang, W. Q., Guo, J. H., Zhang, X., Yu, M., Chung, Y. W., Ruan, Y. C., & Chan, H. C. (2017) · Endocrinology · doi:10.1210/en.2017-00282 · Cited by 31
Berlin, I., Sachon, C., & Grimaldi, A. (2005) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70191-x · Cited by 29
“Defective counter-regulation to hypoglycaemia [1], repeated hypoglycaemic episodes resulting in defective central nervous system glucose sensing [2], hypoglycaemia-associated autonomic failure [3], autonomic neuropathy [4], older age [5] and reduced beta-adrenergic sensitivity [5-8] may all lead alone or combined to t…”
BackgroundYong, Y.-M., Shin, K.-M., Lee, K., Cho, J., Ko, S.-H., Yoon, M.-H., Kim, T.-W., Jeong, J., Park, Y.-M., Ko, S.-H., et al. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.2.154 · Cited by 30
“Hypoglycemia is a well-known acute complication of diabetes treatment and is considered a main barrier to achieving glycemic goals in patients with type 2 diabetes [20-22].”
BackgroundBergenstal, R. M., Rosenstock, J., Bastyr, E. J., PRINCE, M. J., Qu, Y., & Jacober, S. J. (2014) · Diabetes Care · doi:10.2337/dc12-2621 · Cited by 31
“Hypoglycemia is a major limiting factor for insulin-treated patients in achieving optimal glycemic control (4).”
BackgroundKnowledge of insulin use and its determinants among Nigerian insulin requiring diabetes patients
Jasper, U. S., Opara, M. C., Pyiki, E. B., & Akinrolie, O. (2014) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/2251-6581-13-10 · Cited by 33
“Hypoglycemia, especially in insulin treated patients, is the leading limiting factor in the glycemic management of type 1 and type 2 diabetes [10].”
BackgroundSelf-Reported Frequency and Impact of Hypoglycemic Events in Spain
Orozco‐Beltrán, D., Mezquita‐Raya, P., de Arellano, A. R., & Galán, M. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0057-z · Cited by 29
Rege, N. K., Wickramasinghe, N. P., Tustan, A. N., Phillips, N. F. B., Yee, V. C., Ismail‐Beigi, F., & Weiss, M. A. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003650 · Cited by 31
“Continuous and flat 24-h insulin activity (“peakless” basal formulations) is of clinical interest in the treatment of Type 1 and Type 2 diabetes mellitus to reduce the risk of hypoglycemia (especially at night) at a given level of glycemic control (98).”
BackgroundEby, E. L., Zagar, A. J., Wang, P., Curtis, B. H., Xie, J., Haldane, D. C., IDRIS, I. R., Peters, A. L., Hood, R. C., & Jackson, J. A. (2014) · Endocrine Practice · doi:10.4158/ep13407.or · Cited by 28
Minimizing Morbidity of Hypoglycemia in Diabetes: A Review of Mini-Dose Glucagon
Chung, S. T., & Haymond, M. W. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814547518 · Cited by 31
Optimal management of type 2 diabetes in patients with increased risk of hypoglycemia
Taylor, J., Anderson, M., Powell, J., & Campbell, K. M. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s48896 · Cited by 38
“Individuals with diabetes need their treatment optimized to achieve and maintain euglycemia safely.(6) This manuscript will discuss treatment options available in the US for type 2 diabetes and their potential likelihood for hypoglycemia.”
BackgroundHypoglycemia as an indicator of good diabetes care:
Rodriguez-Gutierrez, R., Lipska, K. J., McCoy, R. G., Ospina, N. S., Ting, H. H., Montori, & Hypoglycemia as a Quality Measure in Diabetes Study Group (2016) · BMJ · doi:10.1136/bmj.i1084 · Cited by 27
Gingras, V., Haidar, A., Messier, V., Legault, L., Ladouceur, M., & RABASA-LHORET, R. P. R. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0043 · Cited by 35
Evans, M., Billings, L. K., Håkan‐Bloch, J., Slothuus, U., Abrahamsen, T. J., Andersen, A., & Jansen, J. P. (2017) · Journal of Medical Economics · doi:10.1080/13696998.2017.1409228 · Cited by 30
Clinical overview of diabetes mellitus as a risk factor for cardiovascular death
Abuelgasim, E., Shah, S., Abuelgasim, B., Soni, N., Thomas, A., Elgasim, M., & Harky, A. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2202038 · Cited by 32
“Hypoglycaemia is a common homeostatic imbalance, primarily affecting patients with type 1 diabetes [74], yet is frequent those with type 2 diabetes.”
BackgroundLittle, S., Chadwick, T., Choudhary, P., Brennand, C., Stickland, J., Barendse, S., Olateju, T., Leelarathna, L., Walkinshaw, E., Tan, H. K., et al. (2012) · BMC Endocrine Disorders · doi:10.1186/1472-6823-12-33 · Cited by 27
“Despite 90 years’ clinical experience with insulin replacement therapy, however, severe hypoglycaemia (SH) remains the major factor limiting optimal glycaemic control [4].”
BackgroundZenz, S., Mader, J. K., Regittnig, W., Brunner, M., Korsatko, S., Boulgaropoulos, B., Magnes, C., Raml, R., Narath, S. H., Eller, P., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01836 · Cited by 28
“In healthy subjects, the epinephrine response to hypoglycemia has also a stimulating effect on the EGP and limits glucose utilization by insulin-sensitive tissues (40, 41).”
BackgroundManagement of Diabetes-related Hypoglycemia
Boyle, P. J., & Zrebiec, J. F. (2007) · Southern Medical Journal · doi:10.1097/01.smj.0000242864.17631.a2 · Cited by 34
“Hypoglycemic episodes with long-acting sulfonylureas can be prolonged, particularly in elderly patients with insufficient food intake or comorbidities such as hepatic or renal insufficiency.(10,25,85) Oral agents alone seldom achieve the desired glycemic control over the long term,(86,87) and combining an oral agent w…”
BackgroundClinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin
Schweizer, A., Foley, J. E., Kothny, W., & Åhrén, B. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s40972 · Cited by 30
“In particular, hypoglycemia is the limiting factor in glycemic management for insulin-treated patients with T2DM, 18 and incretin-based therapies have a low hypoglycemic potential.”
Diabetes for Cardiologists: Practical Issues in Diagnosis and Management
Mancini, G. B. J., CHENG, A. Y. Y., Connelly, K. A., FITCHETT, D. H., Goldenberg, R., Goodman, S. G., Leiter, L. A., Lonn, E., Paty, B. W., Poirier, P., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.07.512 · Cited by 29
Update on Clinical Utility of Continuous Glucose Monitoring in Type 1 Diabetes
Haviland, N., Walsh, J. S. A., Roberts, R., & Bailey, T. S. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0808-5 · Cited by 30
Mu, P., Chen, Y., Lu, H., Wen, X., Zhang, Y., Xie, R., Shu, J., Wang, M., & Zeng, L. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1292 · Cited by 30
“This was partly due to physicians’ and patients’ psychological resistance to the initiation of insulin [9,10], the risk of hypoglycaemia [11], concerns about insulin injection [12] and lifestyle restrictions [10].”
BackgroundA novel nasal powder formulation of glucagon: toxicology studies in animal models
Reno, F. E., Normand, P., McInally, K., Silo, S., Stotland, P., Triest, M., Carballo, D., & Piché, C. A. (2015) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-015-0026-9 · Cited by 28
“Indeed, if it were not for the barrier of hypoglycemia, people with diabetes could probably have normal blood glucose levels and thus avoid the complications associated with hyperglycemia [1].”
BackgroundSpeight, J., Barendse, S., Singh, H., Little, S. A., Rutter, M. K., Heller, S. R., & Shaw, J. (2014) · SAGE Open Medicine · doi:10.1177/2050312114527443 · Cited by 30
Pax6 Is a Key Component of Regulated Glucagon Secretion
Gosmain, Y., Cheyssac, C., Masson, M. H., Guérardel, A., Poisson, C., & Philippé, J. (2012) · Endocrinology · doi:10.1210/en.2012-1425 · Cited by 36
Zecchin, C., Facchinetti, A., Sparacino, G., Man, C. D., Manohar, C. U., Levine, J. A., Basu, A., Kudva, Y. C., & Cobelli, C. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0105 · Cited by 28
Assessing the value of the Ambulatory Glucose Profile in clinical practice
Matthaei, S. (2014) · British Journal of Diabetes · doi:10.15277/bjdvd.2014.045 · Cited by 27
Optimal Glycaemic Control in Elderly People with Type 2 Diabetes: What Does the Evidence Say?
Mathur, S., Zammitt, N. N., & Frier, B. M. (2014) · Drug Safety · doi:10.1007/s40264-014-0247-7 · Cited by 30
Jafar, A., Fathi, A. E., & Haidar, A. (2021) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2021.105936 · Cited by 30
Gerada, Y., Mengistu, Z., Demessie, A., Aregay, A. F., & Gebrekidan, K. G. (2017) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/s40200-017-0309-3 · Cited by 27
“The patients with DM are also at a high risk of acute complications like hypoglycemia [4].”
BackgroundPedersen‐Bjergaard, U., Dhamrait, S. S., Sethi, A. A., Frandsen, E., Nordestgaard, B. G., Montgomery, H., Pramming, S., Hougaard, P., & Thorsteinsson, B. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.12.002 · Cited by 28
de Galan, B. E., de Mol, P., Wennekes, L., Schouwenberg, B. J. J., & Smits, P. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0528 · Cited by 31
Hopkins, D. (2004) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2004.07.009 · Cited by 29
“In non-diabetic individuals, glucose counterregulation provides a physiologic defense against falling glucose levels; increased glucagon secretion stimulates hepatic glycogenolysis and favors gluconeogenesis, while release of epinephrine, cortisol and growth hormone facilitates the mobilization of substrates for gluco…”
BackgroundHendrychova, T., Vytrisalova, M., Smahelova, Vlček, J., & Kubena (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s47750 · Cited by 25
“On the other hand, the treatment of the condition is associated with a high risk of acute complications, particularly hypoglycemia.(2) The prevention and control of both types of complications are significantly influenced by adherence to treatment.”
Intelligent technologies for real-time biomedical engineering applications
Nguyen, H. T. (2008) · International Journal of Automation and Control · doi:10.1504/ijaac.2008.022181 · Cited by 29
Chowdhury, G. M. I., Wang, P., Ciardi, A., Mamillapalli, R., Johnson, J., Zhu, W., Eid, T., Behar, K. L., & Chan, O. T. M. (2017) · Diabetes · doi:10.2337/db16-1589 · Cited by 24
“The imperfections of current insulin treatment regimens, coupled with a compromised ability to counter falling glucose levels, increase patient susceptibility to hypoglycemic events (2,3).”
BackgroundFactors affecting hypoglycemia awareness in insulin-treated type 2 diabetes
Murata, G. H., Duckworth, W. C., Shah, J. H., Wendel, C. S., & Hoffman, R. M. (2004) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2003.11.013 · Cited by 30
Cardiovascular Disease Predicts Severe Hypoglycemia in Patients with Type 2 Diabetes
Yun, J., Ko, S., Ko, S.-H., Song, K., Yoo, K., Yoon, K., Park, Y., & Ahn, Y. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.6.498 · Cited by 26
“Hypoglycemia is a well-recognized side effect of diabetes treatment and is regarded as a major barrier to achieving glycemic targets in patients with type 2 diabetes [10], and the incidence of hypoglycemia has continued to increase.”
BackgroundEscaping the Hemoglobin A1c-Centric World in Evaluating Diabetes Mellitus Interventions
Vigersky, R. A. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815576363 · Cited by 27
“Indeed, Cryer has stated that hypoglycemia is the most important limitation in achieving better glycemic control in patients with both type 1 and type 2 diabetes.(3) The importance of hypoglycemia in understanding glucose data has been further emphasized by Rodbard, who suggests that glucose data should be semilogarit…”
BackgroundÖzçelik, S., Çelik, M., Vural, A., Aydın, B., Özçelik, M., & Gözü, H. I. (2020) · Archives of Medical Science · doi:10.5114/aoms.2020.93264 · Cited by 24
Qvisth, V., Toft, E., Enoksson, S., Moberg, E., Arner, P., & Bolinder, J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0859 · Cited by 28
“because hypoglycemia is the most powerful elicitor of endogenous epinephrine release (21).”
BackgroundBulsara, M. K., Holman, C. D. J., van BOCKXMEER, F. M., Davis, E. A., Gallego, P., Beilby, J. P., Palmer, L. J., Choong, C. S., & Jones, T. W. (2007) · Diabetologia · doi:10.1007/s00125-007-0613-4 · Cited by 31
Effects of relative hypoglycemia on LTP and NADH imaging in rat hippocampal slices
Sadgrove, M. P., Beaver, C. J., & Turner, D. A. (2007) · Brain Research · doi:10.1016/j.brainres.2007.06.052 · Cited by 25
“These hypoglycemic episodes can produce both acute and chronic cognitive dysfunction [2,3,9,35].”
BackgroundMcTavish, L., Krebs, J. D., Weatherall, M., & Wiltshire, E. J. (2015) · Diabetic Medicine · doi:10.1111/dme.12730 · Cited by 26
The Accuracy of Home Glucose Meters in Hypoglycemia
Sonmez, A., Yilmaz, Z., Uckaya, G., Kilic, S., Tapan, S., Taslipinar, A., Aydogdu, A., Yazici, M., Yilmaz, M. I., Serdar, M., et al. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0183 · Cited by 23
“3,4 However, not all the hypoglycemic events are symptomatic, and HGMs may not be sensitive enough to detect hypoglycemia.”
Mezquita‐Raya, P., Reyes‐García, R., Moreno, Ó., Muñoz‐Torres, M., Merino-Torres, J. F., Martínez, J. J. G., Jódar-Gimeno, E., Escalada, J., Gargallo-Fernández, M., Soto-González, A., et al. (2013) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2013.04.005 · Cited by 32
Nguyen, H. T., Ghevondian, N., Nguyen, S. T., & Jones, T. W. (2007) · Conference proceedings · doi:10.1109/iembs.2007.4352995 · Cited by 25
“As glucose levels continue to fall, a number of redundant glucose counter-regulatory factors are sequentially activated at specific thresholds to ensure sufficient glucose uptake to the brain and other central nervous system tissue metabolism [4].”
BackgroundMatveyenko, A. V., Bohland, M., Saberi, M., & Donovan, C. M. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00283.2007 · Cited by 22
“, the insulin regimen, type of insulin, exercise regimen, meal composition, and the site and timing of insulin injections, both glucose sensory loci and their potential impairment hold clinical significance (7, 9).”
BackgroundZhou, H., Zhang, T., Oseid, E. A., Harmon, J. S., Tonooka, N., & Robertson, R. P. (2007) · Endocrinology · doi:10.1210/en.2006-1375 · Cited by 28
“Repeated bouts of hypoglycemia lead to decreased intensity of the symptoms, and they begin at lower glucose levels (1).”
BackgroundPhysiological and Behavioral Aspects of Glycemic Control and Hypoglycemia in Diabetes
Boyle, P. J., & Zrebiec, J. F. (2007) · Southern Medical Journal · doi:10.1097/01.smj.0000242866.81791.70 · Cited by 27
“hypoglycemia unawareness may not experience such symptoms until their plasma glucose concentration is much lower.(15) This syndrome is worse in patients who have had frequent hypoglycemic episodes.”
BackgroundRadermecker, R. P., Remy, A. S., Scheen, A. J., Bringer, J., & Renard, É. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.08.001 · Cited by 22
Hirsch, I. B., & Verderese, C. A. (2017) · Endocrine Practice · doi:10.4158/ep171962.ra · Cited by 22
Suthakaran, C., Kishore, U., Anjana, R. M., Unnikrishnan, R., & Mohan, V. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0120 · Cited by 24
Acute consequences of hypoglycaemia in diabetic patients
Halimi, S. (2010) · Diabetes & Metabolism · doi:10.1016/s1262-3636(10)70471-7 · Cited by 28
Update on strategies limiting iatrogenic hypoglycemia
Bonaventura, A., Montecucco, F., & Dallegri, F. (2015) · Endocrine Connections · doi:10.1530/ec-15-0044 · Cited by 26
Role of iron in diabetes mellitus and its complications
Nasr, M., Shaaban, M. A., & Dawood, A. E. D. (2016) · Menoufia Medical Journal · doi:10.4103/1110-2098.178938 · Cited by 22
Zhong, V. W., Juhaeri, J., Cole, S. R., Shay, C. M., Gordon‐Larsen, P., Kontopantelis, E., & Mayer‐Davis, E. J. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.10.008 · Cited by 23
Sources of Glycemic Variability—What Type of Technology is Needed?
Kildegaard, J., Christensen, T. F., & Hejlesen, O. K. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300448 · Cited by 24
Hypoglycemia Reduction and Accuracy of Continuous Glucose Monitoring
Kovatchev, B. P. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0144 · Cited by 24
“Many, now classic, studies have established links among intensive insulin therapy, hypoglycemia unawareness, and impaired counterregulation and concluded that recurrent hypoglycemia spirals into a ‘‘vicious cycle’’ implicated as the principal factor limiting intensive treatment of diabetes.(7,8) Despite the progress o…”
BackgroundSreenan, S., Andersen, M., Thorsted, B. L., Wolden, M. L., & Evans, M. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0075-x · Cited by 21
“Hypoglycemic events or fear of such events has been identified as the major treatment-limiting factors in titrating insulin to optimal glycemic targets in T2DM [16, 17].”
BackgroundHypoglycaemia and its management in primary care setting
Ibrahim, M., Baker, J., Cahn, A., Eckel, R. H., El Sayed, N. A., Fischl, A. H., Gaede, P., Leslie, R. D., Pieralice, S., Tuccinardi, D., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3332 · Cited by 21
The Impact of Nocturnal Hypoglycemia on Sleep in Subjects With Type 2 Diabetes
Jennum, P., Stender-Petersen, K. L., Rabøl, R., Jørgensen, N. R., Chu, P.-L., & Madsbad, S. (2015) · Diabetes Care · doi:10.2337/dc15-0907 · Cited by 28
Patient safety and minimizing risk with insulin administration – role of insulin degludec
Atkin, S. L., & Aye, M. (2014) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s59566 · Cited by 31
The Role of Hypoglycemia in Cardiovascular Outcomes in Diabetes
Paty, B. W. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.09.009 · Cited by 26
Professional flash continuous glucose monitoring as a supplement to A1C in primary care
Hirsch, I. B. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1383137 · Cited by 25
“icians should ask: Can the balance between risk of hypoglycemia and optimal glycemic control be improved [49,50,56]?”
BackgroundRuan, Y., Bally, L., Thabit, H., Leelarathna, L., Hartnell, S., Tauschmann, M., Wilinska, M. E., Evans, M. L., Mader, J. K., Kojzar, H., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13304 · Cited by 22
Choudhary, P., de Portu, S., Arrieta, A., Castañeda, J., & Campbell, F. (2019) · Diabetic Medicine · doi:10.1111/dme.14043 · Cited by 23
Cerebral glutamate metabolism during hypoglycaemia in healthy and type 1 diabetic humans
Bischof, M. G., Brehm, A., Bernroider, E., Krššák, M., Mlynárik, V., Krebs, M., & Roden, M. (2006) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2006.01615.x · Cited by 23
It's Time to Move from the A1c to Better Metrics for Diabetes Control
Kowalski, A. J., & Dutta, S. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0060 · Cited by 22
“The major limitation in restoring normoglycemia in patients with diabetes is hypoglycemia, 11,12 and the HbA1c provides no context for hypoglycemia exposure.”
Zarowitz, B. J. M., & Conner, C. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.pt2.55s · Cited by 20
“Intensive glycemic control is associated with an increased frequency of hypoglycemia,(4) and studies suggest that hypoglycemia may be a major barrier to the achievement of goal A1C values.(18) Hypoglycemia may occur in patients being treated with certain oral agents or insulin.”
BackgroundTreatment with insulin detemir or NPH insulin in children aged 2-5 yr with type 1 diabetes mellitus
Thalange, N. K. S., Bereket, A., Larsen, J., Hiort, L. C., & Peterkova, V. A. (2011) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2010.00750.x · Cited by 21
“Intensive insulin therapy in adults has been shown to reduce the complications of T1DM; however, this was at the cost of high rates of hypoglycaemia and inappropriate weight gain (30, 31), leading to caution in extending intensive insulin therapy to children, especially to the very young.”
BackgroundJensen, M. H., Mahmoudi, Z., Christensen, T. F., Tarnow, L., Seto, E., Johansen, M. D., & Hejlesen, O. K. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296813511744 · Cited by 20
“These adverse effects are fatal in severe cases, and thus are of great concern, leading to potential lack of compliance with intensive insulin therapy.(3,4) Self-monitoring of blood glucose (SMBG) has become the standard approach of glucose monitoring.”
BackgroundTemporal and Geographic Patterns of Hypoglycemia among Hospitalized Patients with Diabetes Mellitus
Bailon, R. M., Cook, C. B., Hovan, M. J., Hull, B. P., Seifert, K. M., Miller-Cage, V., Beer, K. A., Boyle, M. E., Littman, S. D., Magallanez, J. M., et al. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300206 · Cited by 19
Dusaulcy, R., Handgraaf, S., Heddad-Masson, M., Visentin, F., Vesin, C., Reimann, F., Gribble, F. M., Philippé, J., & Gosmain, Y. (2015) · Endocrinology · doi:10.1210/en.2015-1725 · Cited by 25
“Furthermore, the secretory response of α cells to low glucose concentrations is impaired in “long-standing” diabetes, increasing the risk of severe hypoglycemia, especially in patients treated with insulin (5,6).”
BackgroundFarhat, R., Aiken, J., D'Souza, N. C., Appadurai, D., Hull, G., Simonson, E., Liggins, R. T., Riddell, M. C., & Chan, O. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14652 · Cited by 27
“As hypoglycaemia accounts for 2%-4% of mortality in patients with T1D and adds considerably to patient burden while living with the disease, finding therapeutic strategies to improve or restore glucagon secretion can help to prevent or reduce hypoglycaemia onset in these individuals.(6-9) Received: 15 October 2021 Rev…”
BackgroundChristesen, H. T., Brusgaard, K., & Hussain, K. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04250.x · Cited by 21
Farcaşiu, E., Iványi, T., Możejko-Pastewka, B., Birkus, Z., Csog, J., Kowalska, I., Coetzer, T. F., Bulgurlu, S. S., Schinzel, B., & Kiljanski, J. I. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.10.001 · Cited by 19
Nguyen, H. T., Ghevondian, N., & Jones, T. W. (2009) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/iembs.2009.5335144 · Cited by 24
Davies, M. J., Evans, R., Storms, F., Gomis, R., & Khunti, K. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00652.x · Cited by 22
Moser, O., Tschakert, G., Mueller, A., Groeschl, W., Hofmann, P., Pieber, T. R., Lawrence, J. B., & Koehler, G. (2017) · Asian Journal of Sports Medicine · doi:10.5812/asjsm.42160 · Cited by 22
Iavicoli, I., Gambelunghe, A., Magrini, A., Mosconi, G., Soleo, L., Vigna, L., Trevisan, R., Bruno, A., Chiambretti, A., Scarpitta, A. M., et al. (2018) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2018.10.012 · Cited by 23
Farhy, L. S., Du, Z., Zeng, Q., Veldhuis, P. P., Johnson, M. L., Brayman, K. L., & McCall, A. L. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90372.2008 · Cited by 22
Gap junction coupling and islet delta-cell function in health and disease
MIRANDA, C. A., Samad, M., Vergari, E., & Briant, L. J. B. (2021) · Peptides · doi:10.1016/j.peptides.2021.170704 · Cited by 24
Tobin, G. S., Cavaghan, M. K., Hoogwerf, B. J., & McGill, J. B. (2012) · International Journal of Clinical Practice · doi:10.1111/ijcp.12032 · Cited by 23
Drab, S. R. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.pt2.43s · Cited by 18
Wang, W., Gao, Y., Chen, D., Wang, C., Feng, X., & Ran, X. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.05.007 · Cited by 19
“Additionally, as the poor beta-cell function may be prone to episodes of hypoglycemia during intensive insulin therapy among these patients [7], they might keep away from hypoglycemic events at the cost of well glycemic control.”
BackgroundReduction of glycemic variability with Degludec insulin in patients with unstable diabetes
Henao, D. C., Múñoz, Ó., Gómez, A. M., Rondón, M., Colon, C. A., Chica, L. G., Rubio, C., Vargas, F. M. L., Calvachi, M. A., & Perea, A. M. (2018) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2018.03.003 · Cited by 21
Mezquita‐Raya, P., Reyes‐García, R., Moreno, Ó., Muñoz‐Torres, M., Merino-Torres, J. F., Martínez, J. J. G., Jódar-Gimeno, E., Martín, J. E. S., Gargallo-Fernández, M., Soto-González, A., et al. (2013) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2013.11.009 · Cited by 27
Choudhary, P., Lonnen, K., Emery, C., Macdonald, I. A., MacLeod, K. M., Amiel, S. A., & Heller, S. R. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02759.x · Cited by 20
Kristensen, P. L., Tarnow, L., Bay, C., Nørgaard, K., Jensen, T., Parving, H. ‐., Perrild, H., Beck‐Nielsen, H., Christiansen, J. S., Thorsteinsson, B., et al. (2017) · Diabetic Medicine · doi:10.1111/dme.13317 · Cited by 22
Association between hypoglycemia risk and hemoglobin A1C in patients with type 2 diabetes mellitus
Yu, S., Fu, A. Z., Engel, S. S., Shankar, R. R., & Radican, L. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1176017 · Cited by 25
Internet Blood Glucose Monitoring Systems Provide Lasting Glycemic Benefit in Type 1 and 2 Diabetes
Tildesley, H. D., Po, M. D., & Ross, S. A. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.08.019 · Cited by 20
“This dose-limiting toxicity is important clinically, because of the intrinsic adverse effects of hypoglycemia, and also because of its psychological effect, whereby fear of hypoglycemia delays treatment implementation and reduces treatment adherence.(31) Several studies reporting overall and severe hypoglycemic episod…”
BackgroundChallenges of Diabetes Management in Toddlers
Deeb, A. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0130 · Cited by 24
“23 Concerns about hypoglycemia can be expressed by mothers early on at the adjustment stage following diabetes diagnosis.”
Fathi, A. E., Fabris, C., & Breton, M. D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.795895 · Cited by 19
Increasing awareness of hypoglycaemia in patients with Type 2 diabetes treated with oral agents
Barnett, A. H., Brice, R., Hanif, W., James, J., & Langerman, H. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.834250 · Cited by 20
Metadata
- Authors
- Cryer, P.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Cryer, P.
- Venue
- Diabetologia
- Published
- 2002-06
- Volume
- 45
- Issue
- 7
- Pages
- 937-948
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2124282046
- Semantic Scholar
- ebdcc733bdd208ee1005932d38511abefb8034d6
- Cited by
- 794
- References
- 58
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 11 · 2023: 15 · 2022: 16 · 2021: 22 · 2020: 18 · 2019: 24 · 2018: 39 · 2017: 49 · 2016: 32 · 2015: 60 · 2014: 65 · 2013: 66 · 2012: 53
- FWCI
- 12.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p60dk020579-35)
- National Institute of Diabetes and Digestive and Kidney Diseases (R37DK027085, P60-DK20579, R37-DK27085, T32 DK07120, T32DK007120)
- National Center for Research Resources (M01-RR00036, M01RR000036)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Patient Safety and Medication Errors
- Keywords
- hypoglycemia, hypoglycemia unawareness, glucose counterregulation, insulin excess, epinephrine response, glucagon response, type 1 diabetes, type 2 diabetes, glycemic control
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Epinephrine, Glucagon, Humans, Hypoglycemia, Insulin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.